Wall Street brokerages predict that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will post $1.49 billion in sales for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings. The lowest sales estimate is $1.41 billion and the highest is $1.53 billion. Regeneron Pharmaceuticals posted sales of $1.23 billion in the same quarter last year, which would indicate a positive year over year growth rate of 21.1%. The firm is scheduled to announce its next quarterly earnings results on Thursday, February 8th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year sales of $1.49 billion for the current year, with estimates ranging from $5.69 billion to $5.86 billion. For the next year, analysts forecast that the company will post sales of $6.27 billion per share, with estimates ranging from $5.89 billion to $6.76 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that that provide coverage for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter last year, the company posted $3.13 EPS.

REGN has been the topic of several research reports. Leerink Swann restated a “positive” rating and set a $552.00 price objective (down previously from $580.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. BMO Capital Markets set a $444.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, November 27th. Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $480.00 to $380.00 in a research report on Friday, December 1st. Robert W. Baird raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a report on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $467.84.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at $381.32 on Tuesday. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The firm has a market cap of $40,910.63, a price-to-earnings ratio of 32.97, a PEG ratio of 1.50 and a beta of 1.53. Regeneron Pharmaceuticals has a 52-week low of $340.09 and a 52-week high of $543.55.

In other Regeneron Pharmaceuticals news, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares in the company, valued at $4,950,000. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The disclosure for this sale can be found here. Insiders own 10.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of REGN. Fieldpoint Private Securities LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $130,000. Sterling Investment Advisors Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 28 shares during the last quarter. FNY Partners Fund LP boosted its position in shares of Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares during the last quarter. IFP Advisors Inc raised its stake in Regeneron Pharmaceuticals by 33.2% during the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 96 shares in the last quarter. Finally, Vident Investment Advisory LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at $200,000. Institutional investors and hedge funds own 66.67% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Brokerages Expect Regeneron Pharmaceuticals, Inc. (REGN) Will Post Quarterly Sales of $1.49 Billion” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/brokerages-expect-regeneron-pharmaceuticals-inc-regn-will-post-quarterly-sales-of-1-49-billion/1758851.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.